Migraine prophylaxis is likely to be improved by a new wave of monoclonal antibody-based treatments that act on calcitonin gene related peptide (CGRP), according to a ‘headache update’ presentation at ANZAN 2019. Dr Bronwyn Jenkins, a consultant neurologist in Sydney with a special interest in headache, said it had taken more than 30 years since ...
CGRP mAbs will offer new opportunities for migraine prophylaxis
By Michael Woodhead
28 May 2019